Some strains of staphylococci have raised MBCs of quinupristin/dalfopristin compared with their MICs. In this study, the time-kill kinetics of quinupristin/dalfopristin at 2 mg/L on two strains of Staphylococcus aureus were determined by viable count and intracellular ATP measurement. After 24 h exposure to quinupristin/dalfopristin, the percentage survival of the strain with a raised MBC was 5.9 and that of the strain with a normal MBC was 0.04. The time-kill kinetics of the strain with a raised MBC were analogous to those associated with phenotypic tolerance.
Introduction
Quinupristin/dalfopristin, a new semisynthetic parenterally administered streptogramin antibiotic, is a 30:70 mixture of two water-soluble compounds, quinupristin and dalfopristin, derived from natural pristinamycins I A and II A , respectively. 1 Streptogramin antibiotics are similar in their mechanism of action to macrolides and lincosamides in that they inhibit protein synthesis in bacteria by affecting ribosome function. The proposed mechanism of action of quinupristin/dalfopristin is that protein synthesis is inhibited by conformational modification of the region of the bacterial ribosome where peptidyltransferase acts. This in turn may decrease the hydrolytic activity of peptidyl-tRNA hydrolase leading to a tRNA 'auxotrophy' and bacterial cell death. 2 A previous study of the in-vitro activity of quinupristin/dalfopristin demonstrated that 17 of 50 Staphylococcus aureus strains tested had MBCs at least four-fold higher than their MICs and some strains had an MBC up to 16-fold higher. 3 Six strains are known to be resistant to macrolide, lincosamide and streptogramin B type (MLS B ) antibiotics. It was not obvious from the MIC which strains would exhibit raised MBCs. Further investigations were performed to study the mechanism and clinical relevance of the strains exhibiting raised MBCs.
Time-kill kinetics demonstrate the bactericidal activity of a fixed concentration of an antimicrobial agent on a bacterial culture; they can also be used to differentiate between phenotypic and genetic tolerance. 4 Phenotypic tolerance is defined as decreased susceptibility to antimicrobials under certain growth conditions, and genetic tolerance occurs if an organism possesses a unique genetic property such as a defective autolytic system. 4 Tolerant strains usually exhibit high MBCs relative to their MICs. This report compares the time-kill kinetics of quinupristin/ dalfopristin at a concentration of 2 mg/L on an S. aureus strain that had a raised MBC of quinupristin/dalfopristin with one without a raised MBC. Quinupristin/dalfopristin has MIC 90 values of 2 mg/L against most strains of staphylococci. 5, 6 The time-kill kinetics were evaluated by viable counting and intracellular ATP determination by bioluminescence. Viable counts, the conventional method used to follow growth kinetics, were compared with bacterial ATP concentrations, a metabolic measure of antimicrobial sensitivity which could reveal subtle differences, undetected by viable counting, since surviving organisms do not always form colonies on agar plates.
Materials and methods
The clinical isolates of S. aureus studied were F31 (normal MBC, MLS B -sensitive) and F457 (raised MBC, constitutively MLS B -resistant). The quinupristin/dalfopristin MIC and MBC results determined previously 7 for F31 and F457 were 0.25 and 0.25 mg/L, and 1 and 16 mg/L, respectively. Inocula of 10 8 and 10 6 cfu/mL were studied in log and stationary growth phases. An overnight Iso-Sensitest broth (Unipath, Basingstoke, UK) culture of each organism was diluted 1:10 and 1:1000 into prewarmed IsoSensitest broth to produce inocula of approximately 10 8 and 10
6 cfu/mL, respectively. These were shaken aerobically in a water bath at 37°C for 1 h to allow the organisms
29
Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods to reach logarithmic growth phase. For the stationary phase inocula the above dilutions were performed just before antibiotic addition. A stock solution of quinupristin/dalfopristin (1000 mg/L) was prepared in sterile distilled water, filter sterilized and added to the cultures to give a final concentration of 2 mg/L. For each organism, antibiotic-free controls were included for each growth phase and inoculum. The cultures were placed in a shaking water bath at 35-37°C and incubated for the duration of the study.
Viable counting
Viable counts were determined on 5% horse blood agar plates at 0, 4, 8 and 24 h after appropriate dilution in phosphate-buffered saline pH 7.3 (Unipath) with a spiral plater (Don Whitley, Skipton, UK) and after 48 h incubation at 35-37°C the colonies were counted. Means of three replica viable counts (cfu/mL) were plotted logarithmically against time.
Intracellular ATP determination
Intracellular ATP was determined at 0, 4, 8 and 24 h. The culture samples were incubated with 0.04% apyrase grade I (Sigma Chemical Co. Ltd, Poole, UK) for 10 min at 37°C to remove any extracellular ATP present. ATP was extracted from the bacterial samples by incubation at room temperature for 10 min with an equal volume of 2% trichloroacetic acid (TCA) (BDH Merck Ltd, Poole, UK) containing 0.04 M ethylenediaminetetraacetic acid (EDTA) (BDH Merck Ltd) which inhibits ATPhydrolysing enzymes. The samples were then diluted with Tris-acetate buffer and 2 mM EDTA (Bio Orbit, Turku, Finland) and an aliquot was then assayed with firefly luciferin-luciferase ATP monitoring reagent (Bio Orbit) on a 1251 luminometer (Bio Orbit). ATP concentrations of samples were calculated based on the luminescence produced and calibrated by an internal ATP standard. The mean of two replica ATP values ( mol/mL) were plotted logarithmically against time.
Results
Figures 1 and 2 illustrate the time-kill kinetics of 2 mg/L quinupristin/dalfopristin on S. aureus strains F31 (normal MBC) and F457 (raised MBC), respectively, in log phase evaluated by viable counts and intracellular ATP determinations.
The ATP values throughout exhibited good correlation with viable counts for the unexposed control cultures, although less correlation was observed between ATP values and viable counts in the antibiotic-exposed cultures. The log phase cultures of both strains were more susceptible to quinupristin/dalfopristin than the stationary phase cultures, as shown by the bactericidal rates (change in log 10 cfu/mL from 0 to 4 h) (Table) . The bactericidal rates were 1.62 and 1.41 for log phase cultures and 0.58 and 0.05 for stationary phase cultures, at inocula of 10 6 cfu/mL of F31 and F457, respectively. Quinupristin/ dalfopristin exhibited more bactericidal activity against the 10 6 cfu/mL inoculum than the 10 8 cfu/mL inoculum in both growth phases (Table) .
As expected, quinupristin/dalfopristin at 2 mg/L exhibited more bactericidal activity on S. aureus strain F31 than on strain F457.
For log phase cultures with initial inocula of 10 6 cfu/mL, the two S. aureus strains exhibited different reductions in viable counts over the test period.
Discussion
Time-kill kinetic techniques demonstrated a better correlation with in-vivo efficacy than other methods of determining bactericidal activity; time-kill kinetic techniques are also the most reliable method for determining and differentiating tolerance. Conventional viable counts allow morphological and culture purity checks to be performed but the method is retrospective, with cfu/mL calculated after 48 h incubation. Intracellular ATP measurement is rapid, data being available 30 min after sampling, and may allow determination of viable but non-culturable organisms, that is organisms that are still synthesizing RNA and protein. 8 The reduced correlation observed between viable counts and intracellular ATP measurement in antibiotic-exposed cultures might be due to viable but non-culturable organisms and might reflect the time difference in data collection between the two methods.
It has been shown that phenotypically tolerant isolates demonstrate time-kill kinetics that exhibit an initial high rate of killing similar to a non-tolerant isolate but with a greater survival rate ( 0.1%), whereas genetically tolerant isolates demonstrate a slow loss of viability over the entire killing curve. 4 The killing curve of log phase F457 with an initial inoculum of 10 6 cfu/mL demonstrated an initially high decrease in viability of 1.4 log 10 cfu/mL at 4 h, similar to that of F31 (1.6 log 10 cfu/mL) at 4 h in the same conditions. F457 had a higher survival rate (5.9% after 24 h), that is the reduction in viability at 24 h was 1.2 log 10 compared with a reduction in viability at 24 h of 3.4 log 10 for F31 (0.04% survival rate after 24 h). From these results it could be speculated that the raised MBC of quinupristin/dalfopristin for F457 is due to phenotypic tolerance, defined as decreased susceptibility to antimicrobials under certain growth conditions. 4 We have previously compared the post-antibiotic effect of quinupristin/dalfopristin on S. aureus strains with and without raised MBCs; 7 no significant differences were observed between the two populations.
The clinical significance and the mechanism of tolerance of S. aureus strains that have raised MBCs of quinupristin/dalfopristin has yet to be determined. Investigators have demonstrated that some constitutive MLS Bresistant S. aureus also have raised MBCs and diminished killing effects in time-kill experiments with quinupristin/ dalfopristin. 9 It has been proposed that clinical treatment with quinupristin/dalfopristin of infections caused by MLS B -resistant S. aureus that require bactericidal activity (e.g. endocarditis) might be successful only against strains with a low quinupristin/dalfopristin MBC. 10 Carefully conducted clinical studies are required to obtain answers to these important questions. 
